PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
ISU Abxis has built a stable revenue base with Gaucher's and Fabry's disease biosimilars, but quarterly earnings remain volatile while the company pursues new growth drivers such as AI-based joint drug research.
2025 annual operating profit stayed positive at KRW 1.63 billion, but net income turned negative at KRW -10.68 billion
Q2 2026 revenue reached KRW 14.93 billion with operating profit of KRW 0.48 billion and owners' net income of KRW 3.17 billion, marking a quarterly improvement
Core products Abcertin (Gaucher's disease) and Fabagal (Fabry's disease) combine stable domestic sales with overseas expansion through a partnership covering Russia and 11 CIS countries
In February 2026, the company signed a joint research agreement with AI drug discovery firm Galux to pursue next-generation rare disease treatments
In March 2026, the company received a one-month clinical trial suspension for GCP violations related to Clotinab, highlighting regulatory risk
Founded in 2001 and listed on KOSDAQ in 2009 through a special technology listing, ISU Abxis is a biopharmaceutical company affiliated with the ISU Group, specializing in antibody and enzyme replacement therapies.
Its main products are Abcertin, a biosimilar of Sanofi's Cerezyme for Gaucher's disease, Fabagal, a biosimilar of Sanofi Genzyme's Fabrazyme for Fabry's disease, and Clotinab, Korea's first antibody-based antithrombotic drug.
Abcertin was launched domestically in 2013 and later expanded exports to Latin America, while Fabagal received conditional domestic approval in 2014 and continues to be marketed.
For overseas growth, the company has a sales partnership with Russia's Petrovax covering Russia and 11 CIS countries, involving technology transfer of bulk drug substance and finished products.
Its new drug pipeline includes ISU104, an ErbB3-targeted anticancer antibody, CAR-NK cell therapy, an anti-ASM antibody candidate for Alzheimer's disease, and a hemophilia B drug being co-developed with U.S.-based Catalyst Biosciences.
In 2026, the company signed a joint research agreement with AI drug discovery firm Galux to pursue next-generation rare disease treatments using protein design technology. ISU Chemical, an ISU Group affiliate, holds a 33.6% stake as the largest shareholder, with CEO Yu Jun-su leading the company.
Competitively, the firm occupies a niche among a small group of domestic rare disease drug developers and global biosimilar makers, leveraging price competitiveness versus originator drugs to build its market position.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩22.8B | ₩9.4B | 41.1% |
| 2025Q3 | ₩15.7B | ₩600M | 3.6% |
| 2025Q4 | ₩10.9B | -₩7.8B | −71.8% |
| 2026Q1 | ₩9.5B | -₩3.4B | −36.4% |
| 2026Q2 | ₩14.9B | ₩500M | 3.2% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩41.2B | -₩16B | -₩7.2B | −38.9% | −11.3% | 113.1% |
| 2023 | ₩54.3B | ₩3.9B | ₩3.6B | 7.2% | 4.7% | 167.8% |
| 2024 | ₩60.3B | ₩13.4B | ₩14.7B | 22.2% | 14.6% | 58.9% |
| 2025 | ₩56.7B | ₩1.6B | -₩10.7B | 2.9% | −9.3% | 38.8% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Annual revenue in 2025 came to KRW 56.67 billion, a slight decrease from KRW 60.26 billion in 2024, while operating profit fell sharply to KRW 1.63 billion from KRW 13.40 billion in 2024.
Net income swung to a loss of KRW -10.68 billion in 2025 from a profit of KRW 14.72 billion in 2024, driven decisively by a deterioration in the fourth quarter.
Indeed, Q4 2025 revenue was KRW 10.93 billion with an operating loss of KRW 7.85 billion and an owners' net loss of KRW 10.89 billion, significantly dragging down annual results.
In contrast, Q2 2025 was the strongest quarter, with revenue of KRW 22.83 billion, operating profit of KRW 9.38 billion, and owners' net income of KRW 9.23 billion.
Moving into 2026, Q1 was again weak with revenue of KRW 9.45 billion and an operating loss of KRW 3.44 billion, but Q2 2026 showed improvement with revenue of KRW 14.93 billion, operating profit of KRW 0.48 billion, and owners' net income of KRW 3.17 billion, turning profitable again.
Over the trailing four quarters (Q3 2025 to Q2 2026), owners' net income remains in negative territory at KRW -8.18 billion. The annual operating margin fell sharply from 22.2% in 2024 to 2.9% in 2025, and compared with 7.2% in 2023 and -38.9% in 2022, the pattern underscores continued quarter-to-quarter volatility.
On the cash flow side, operating cash flow of KRW 11.04 billion in 2025 stood out as favorable despite the net loss, and the debt ratio improved markedly from 167.8% in 2023 to 38.8% in 2025, indicating a strengthened balance sheet.
The rare disease treatment and biosimilar market is expected to see continued growth driven by an aging population and rising chronic disease burdens that increase demand for cost-effective healthcare.
Biosimilars, which replace patent-expired originator biologics, continue to see demand as they typically carry lower development costs and prices, easing strain on national health insurance budgets.
The market for rare genetic disease treatments such as Gaucher's and Fabry's disease, where ISU Abxis operates, is a niche segment with limited patient populations that discourages entry by large pharmaceutical companies, allowing the firm to maintain a stable, quasi-monopolistic position domestically.
Overseas, however, the company must compete with originator developers such as Sanofi, and its partnership in the Russia and CIS region is considered a key variable for future overseas revenue expansion.
In the domestic biosimilar and antibody therapeutics space, several companies including Aprogen, Panagene, and Boryung compete for market share, and recent market attention toward the broader domestic biosimilar theme has been notable.
AI-based drug design technology is spreading across the industry as a way to improve speed and cost efficiency in drug development, and ISU Abxis is seeking to capture this trend through its collaboration with Galux.
The company is pursuing next-generation rare disease drug candidates through its AI-based joint research with Galux, aiming to secure a growth driver following Abcertin and Fabagal, with related reports indicating plans to disclose non-clinical efficacy data for a new drug candidate later in the year.
The partnership with Russia's Petrovax reportedly involves technology transfer of bulk drug substance and finished products through 2025-2026, making progress during this window a relevant indicator for future overseas revenue direction.
Fabagal is understood to be undergoing a domestic Phase 3 trial with the Ministry of Food and Drug Safety, with securing Phase 3 data cited as a precondition for expanding sales to existing export markets.
On the other hand, the Clotinab clinical trial received a one-month suspension (March 18 to April 17, 2026) for GCP violations, warranting monitoring of any resumption and progress going forward.
Early-to-clinical-stage pipeline assets such as the ErbB3-targeted anticancer drug ISU104, CAR-NK therapy, and the Alzheimer's antibody candidate are expected to require considerable time before commercialization.
Government open innovation support policies and broader interest in Korean biotech may provide a favorable environment for further partnerships, but the success of individual projects remains uncertain.
ISU Abxis's share price relative to net asset value tends to trade near or at a modest premium to book value, rather than at an extreme discount or premium.
Since annual results have alternated between profit and loss, earnings-based valuation metrics have shown considerable swings depending on the profitability of each period. Dividend payments have not been made recently, so dividend-related metrics stand at a level that is not particularly notable within the sector.
The decline in the debt ratio from well above 100% in the past to the 30% range more recently can be interpreted as a positive shift in balance sheet stability. However, given the wide swings in quarterly results, the sustainability of any earnings recovery remains an important variable in interpreting valuation.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Abcertin and Fabagal have an established domestic prescription base as rare disease treatments, and the small market size limits new competitor entry. The company has also secured an overseas revenue foundation through its partnership covering Russia and 11 CIS countries. The long-term stability of domestic insurance drug pricing also enhances revenue predictability.
The joint research agreement signed with Galux in February 2026 aims to improve development efficiency using AI-based protein design technology. Galux brings technical credibility from its collaboration experience with global pharma majors including AstraZeneca and Boehringer Ingelheim. If successful, this could provide a next growth driver following Abcertin and Fabagal.
The debt ratio fell sharply from 167.8% in 2023 to 38.8% in 2025, improving financial stability. Operating cash flow in 2025 also came in at a favorable KRW 11.04 billion. This suggests financial capacity to continue investing in the new drug pipeline.
Q4 2025 revenue was KRW 10.93 billion with an operating loss of KRW 7.85 billion, significantly damaging annual results. Q1 2026 was also weak with an operating loss of KRW 3.44 billion. Such quarterly swings make predictable earnings trends difficult to establish.
In March 2026, an unapproved protocol change and non-compliance was found in the Clotinab clinical trial, resulting in a one-month clinical suspension. This exposed a vulnerability in the clinical management process, and the possibility of similar regulatory risk recurring cannot be ruled out.
Fabagal's Phase 3 trial has been delayed for years since its conditional approval in 2014, and the company previously received an approval extension from a central pharmaceutical review committee on the condition it was the 'last chance.' Any further delay in completing Phase 3 could disrupt the strategy to expand sales to existing export markets.
As seen with Clotinab, a recurrence of GCP violations could lead to further administrative penalties or clinical delays. The progress and data timeline of Fabagal's Phase 3 trial also remain sources of uncertainty.
Rare disease treatments face inherent structural challenges in patient recruitment that can delay clinical timelines.
The Russia and CIS partnership is premised on technology transfer of bulk substance and finished products, and progress could be delayed by geopolitical risks or changes in the regulatory environment.
Changes in the business conditions of Petrovax, the contractual partner, could also affect ISU Abxis's overseas revenue.
New drug pipeline assets such as ISU104, CAR-NK therapy, and the AI-based joint research with Galux are mostly at early-to-clinical stages, with commercialization success remaining uncertain.
Drug development is exposed to various risks including clinical trial failure, regulatory delays, and the need for additional funding.
Q3 2026 earnings release will show whether the profitability seen in Q2 continues, and whether cost factors that hurt Q4 last year could recur.
The company has indicated plans to disclose non-clinical efficacy data for a new drug candidate from its joint research with Galux, so the results and timing of this disclosure should be checked.
Progress on the bulk substance and finished product technology transfer with Russia's Petrovax and associated revenue recognition should be tracked.
The resumption status of the Clotinab clinical trial after its suspension, along with the progress of Fabagal's domestic Phase 3 trial, should be monitored together.
ISU Abxis combines a stable revenue base from rare disease treatments Abcertin and Fabagal with an overseas expansion attempt through its Russia-CIS partnership, and its balance sheet shows an improving trend as reflected in the declining debt ratio.
However, annual and quarterly earnings have shown considerable volatility, swinging from a profit in 2024 to a loss in 2025 and back to profitability in Q2 2026, with weakness in Q4 2025 and Q1 2026 heavily influencing annual results.
The clinical trial suspension resulting from a GCP violation involving Clotinab highlighted risk in clinical trial management, and Fabagal's Phase 3 trial also carries a history of delays that warrants continued monitoring.
The AI-based joint drug research agreement signed with Galux in early 2026 represents an attempt to secure a mid-to-long-term growth driver, though considerable time and uncertainty remain before any commercialization.
Overall, this stock reflects a structure where a stable niche market business base and new pipeline expansion potential coexist alongside earnings and clinical management volatility.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.